Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CTSO

Cytosorbents Corp

Nov 22 • 04:00PM ET

0.9200

Dollar change +0.0300
Percentage change 3.37	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT BSX BAX RMD EW DXCM PEN TFX GMED

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	14.48%	Shs Outstand	54.24M	Perf Week	2.79%
Market Cap	52.01M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.00%	Shs Float	46.76M	Perf Month	-12.38%
Income	-18.67M	PEG	-	EPS next Q	-0.07	Inst Own	31.15%	Short Float	2.90%	Perf Quarter	-14.02%
Sales	37.74M	P/S	1.38	EPS this Y	53.12%	Inst Trans	-1.51%	Short Ratio	12.07	Perf Half Y	2.22%
Book/sh	0.24	P/B	3.86	EPS next Y	21.67%	ROA	-39.15%	Short Interest	1.36M	Perf Year	-25.81%
Cash/sh	0.10	P/C	9.14	EPS next 5Y	-	ROE	-118.50%	52W Range	0.70 - 2.15	Perf YTD	-17.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.64%	ROI	-47.42%	52W High	-57.21%	Beta	0.56
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	13.13%	Gross Margin	62.71%	52W Low	31.43%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	33.06%	Oper. Margin	-57.21%	RSI (14)	45.51	Volatility	6.83% 9.93%
Employees	186	Debt/Eq	2.06	Sales Y/Y TTM	1.80%	Profit Margin	-49.47%	Recom	2.00	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	2.03	EPS Q/Q	79.30%	Payout	-	Rel Volume	0.68	Prev Close	0.89
Sales Surprise	-9.39%	EPS Surprise	-45.45%	Sales Q/Q	6.58%	Earnings	Nov 07 AMC	Avg Volume	112.33K	Price	0.92
SMA20	-1.24%	SMA50	-17.33%	SMA200	-6.96%	Trades		Volume	76,870	Change	3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-07-23	Initiated	B. Riley Securities	Buy	$4
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Sep-17-20	Initiated	Jefferies	Buy	$15
Sep-01-20	Initiated	SVB Leerink	Outperform	$15
Aug-08-17	Reiterated	Maxim Group	Buy	$10 → $12
Oct-26-16	Initiated	Aegis Capital	Buy
May-24-16	Initiated	Maxim Group	Buy	$8
Oct-29-15	Upgrade	WBB Securities	Speculative Buy → Buy	$13 → $13
May-12-15	Reiterated	MLV & Co	Buy	$28 → $21
Apr-01-15	Reiterated	MLV & Co	Buy	$28 → $30
Mar-05-15	Initiated	MLV & Co	Buy	$30
Feb-25-15	Initiated	WBB Securities	Speculative Buy	$13
Jan-27-15	Reiterated	H.C. Wainwright	Buy	$1 → $12

Show Previous Ratings

Nov-11-24 07:30AM	CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India (GlobeNewswire) +25.68%
Nov-08-24 04:03PM	CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... (GuruFocus.com) -18.05%
Nov-07-24 05:58PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CytoSorbents Reports Third Quarter 2024 Financial and Operational Results (GlobeNewswire)
Nov-06-24 07:54AM	CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +6.61%
07:00AM	Loading…
Nov-04-24 07:00AM	CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification (GlobeNewswire) -12.95%
Oct-22-24 07:00AM	FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review (GlobeNewswire)
Oct-17-24 07:00AM	CytoSorbents to Report Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-09-24 06:19PM	CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -7.08%
Oct-01-24 07:00AM	CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update (GlobeNewswire) -10.00%
Aug-27-24 07:00AM	CytoSorbents to Present at the H.C. Wainwright 26?? Annual Global Investment Conference (GlobeNewswire)
Aug-16-24 04:05PM	CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-24 05:45PM	CytoSorbents: Q2 Earnings Snapshot (Associated Press Finance) +7.99%
04:19PM	CytoSorbents Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
07:00AM	Loading…
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +7.92%
Aug-01-24 07:00AM	CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-30-24 02:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire)
Jul-29-24 08:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire) +17.48%
Jul-17-24 07:00AM	CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress (GlobeNewswire)
Jul-02-24 07:00AM	CytoSorbents Secures $20 Million Credit Facility (GlobeNewswire) +17.40%
Jun-24-24 07:00AM	CytoSorbents Announces Regulatory Approval of CytoSorb in Taiwan (GlobeNewswire)
Jun-13-24 07:00AM	CytoSorbents Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union (GlobeNewswire)
Jun-05-24 07:00AM	CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting (GlobeNewswire) +5.04%
Jun-04-24 07:00AM	CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract (GlobeNewswire)
May-10-24 12:10PM	Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.30%
May-09-24 04:24PM	CytoSorbents: Q1 Earnings Snapshot (Associated Press Finance) -7.10%
04:17PM	CytoSorbents Reports First Quarter 2024 Results (GlobeNewswire)
May-02-24 07:00AM	CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe (GlobeNewswire)
Apr-26-24 07:00AM	CytoSorbents to Report First Quarter 2024 Operating and Financial Results (GlobeNewswire)
07:00AM	Loading…
Apr-17-24 07:00AM	STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting (GlobeNewswire)
Mar-15-24 10:14AM	Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.27%
06:28AM	Q4 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 09:53PM	CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:39PM	CytoSorbents Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-06-24 07:00AM	CytoSorbents to Report Fiscal 2023 Operating and Financial Results (GlobeNewswire)
Feb-08-24 07:00AM	CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-17-24 07:15AM	Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients (GlobeNewswire)
Dec-28-23 07:00AM	CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation (GlobeNewswire) -33.44%
Dec-16-23 07:01AM	Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO) (GuruFocus.com)
Dec-13-23 09:15AM	CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering (GlobeNewswire) +21.53%
Nov-10-23 09:42AM	Q3 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
08:52AM	Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 05:47PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance) -11.27%
04:15PM	CytoSorbents Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-27-23 07:00AM	CytoSorbents to Report Third Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.83%
Oct-05-23 07:00AM	CytoSorbents to Present at the 8th Annual Dawson James Conference (GlobeNewswire)
Sep-27-23 07:00AM	CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 07:00AM	CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer (GlobeNewswire)
Sep-11-23 11:32AM	CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation (GlobeNewswire)
Sep-01-23 04:43PM	CytoSorbents Announces Resignation of Chief Financial Officer Alexander DAmico (GlobeNewswire)
Aug-31-23 07:00AM	CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil (GlobeNewswire)
Aug-14-23 07:00AM	CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial (PR Newswire)
Aug-03-23 09:10AM	CTSO: CytoSorbents reports 2nd quarter 2023 financial and results which showed strong product revenue growth and an improved cost structure. (Zacks Small Cap Research) -5.07%
Aug-02-23 09:02AM	Q2 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents) -7.46%
Aug-01-23 04:23PM	CytoSorbents: Q2 Earnings Snapshot (AP Finance)
04:15PM	CytoSorbents Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Jul-31-23 07:31AM	Several Insiders Invested In Cytosorbents Flagging Positive News (Simply Wall St.)
Jul-26-23 07:00AM	CytoSorbents to Report Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-19-23 07:00AM	CytoSorbents Appoints Alexander DAmico as Chief Financial Officer (GlobeNewswire)
Jul-11-23 07:00AM	CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease (GlobeNewswire) +11.49%
Jul-09-23 09:00AM	Cytosorbents Corporation's (NASDAQ:CTSO) largest shareholders are retail investors with 52% ownership, institutions own 33% (Simply Wall St.)
Jul-07-23 07:07AM	CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial (GlobeNewswire)
Jun-15-23 07:00AM	CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review (GlobeNewswire)
Jun-05-23 09:00AM	CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-05-23 07:18AM	Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? (Simply Wall St.)
May-04-23 10:31AM	CTSO: CytoSorbents reports 1st quarter 2023 financial and operating results which showed sequential revenue growth on a Core Product constant currency basis. (Zacks Small Cap Research)
May-03-23 07:42AM	Q1 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents) +16.46%
May-02-23 04:23PM	CytoSorbents: Q1 Earnings Snapshot (AP Finance)
04:15PM	CytoSorbents Reports First Quarter 2023 Results (GlobeNewswire)
Apr-26-23 07:00AM	CytoSorbents to Report First Quarter 2023 Operating and Financial Results (GlobeNewswire) -8.89%
Apr-20-23 07:00AM	CytoSorbents Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled (GlobeNewswire)
Apr-19-23 07:00AM	CytoSorbents Announces Board Chairman Al W. Kraus To Retire (GlobeNewswire)
Apr-17-23 10:47AM	Cytosorbents Corporation (NASDAQ:CTSO) Might Not Be As Mispriced As It Looks (Simply Wall St.)
Mar-29-23 08:30AM	Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation (GlobeNewswire)
Mar-22-23 08:09AM	CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) (GlobeNewswire)
Mar-20-23 07:38AM	Investors in Cytosorbents (NASDAQ:CTSO) have unfortunately lost 57% over the last five years (Simply Wall St.)
Mar-17-23 09:10AM	CTSO: UPDATE: CytoSorbents reports 4th quarter and fiscal 2022 financial and operating results which showed positive revenue growth on a Core Product constant currency basis. (Zacks Small Cap Research)
Mar-14-23 07:00AM	CytoSorbents Comments on Bank Exposure and Diversified Cash Position (GlobeNewswire)
Mar-13-23 02:53AM	Cytosorbents Corporation (NASDAQ:CTSO) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-10-23 10:33AM	Q4 2022 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-09-23 04:15PM	CytoSorbents Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-07-23 07:00AM	New European Guidelines for the Management of Severe Perioperative Bleeding Consider Hemoadsorption for the First-Time (GlobeNewswire) +20.25%
Feb-27-23 07:00AM	CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
Feb-24-23 07:00AM	CytoSorbents to Report Fiscal 2022 Operating and Financial Results (PR Newswire)
Feb-21-23 06:22AM	Quite a few insiders invested in Cytosorbents Corporation (NASDAQ:CTSO) last year which is positive news for shareholders (Simply Wall St.)
Feb-15-23 08:20AM	CTSO: INITIATION: Established medical device company with advanced proprietary blood purification technologies positioned for rapid profitable growth going forward. (Zacks Small Cap Research)
Jan-31-23 07:15AM	CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue (PR Newswire) +25.44%
Jan-29-23 09:58AM	Cytosorbents Corporation's (NASDAQ:CTSO) market cap touched US$103m last week, benefiting both individual investors who own 52% as well as institutions (Simply Wall St.)
Jan-23-23 07:00AM	CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial (PR Newswire)
Jan-17-23 07:00AM	CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs (PR Newswire)
Jan-12-23 07:16AM	Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth? (Simply Wall St.) +6.37%
Dec-29-22 07:00AM	CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement (PR Newswire) +17.65%
Dec-21-22 07:00AM	CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications (PR Newswire) +11.65%
Nov-17-22 05:21AM	These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat (Simply Wall St.)
Nov-14-22 07:00AM	CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled (PR Newswire)
Nov-09-22 05:26AM	Cytosorbents Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -7.59%
Nov-03-22 08:15PM	CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.90%
04:15PM	CytoSorbents Reports Third Quarter 2022 Financial and Operational Results (PR Newswire)

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sobel Alan D.	Director	Dec 13 '23	Buy	1.33	22,557	30,001	101,857	Dec 15 04:35 PM
Deliargyris Efthymios	Chief Medical Officer	Dec 13 '23	Buy	1.33	22,557	30,001	348,433	Dec 15 04:34 PM
Capponi Vincent	President & COO	Dec 13 '23	Buy	1.33	18,797	25,000	584,134	Dec 15 04:34 PM
BATOR MICHAEL G.	Director	Dec 13 '23	Buy	1.33	37,594	50,000	125,394	Dec 15 04:33 PM
Jones Edward Raymond	Director	Dec 13 '23	Buy	1.33	7,519	10,000	88,834	Dec 15 04:32 PM
BLOCH KATHLEEN P.	Chief Financial Officer	Dec 13 '23	Buy	1.33	37,594	50,000	467,941	Dec 15 04:32 PM
Kim Jiny	Director	Dec 13 '23	Buy	1.33	7,519	10,000	77,819	Dec 15 04:31 PM
Chan Phillip P.	Chief Executive Officer	Dec 13 '23	Buy	1.33	75,188	100,000	1,068,704	Dec 15 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTSO

Cytosorbents Corp

Upgrade your FINVIZ experience